A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma

Published:2020-09-22 Issue:1 Volume:18 Page:19-27
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clncl Oncology

Author:

Liu Yao‐Chung¹²,Su Chien‐Wei²³,Ko Po‐Shen¹²,Lee Rheun‐Chuan²⁴,Liu Chia‐Jen¹²,Huang Yi‐Hsiang²³,Gau Jyh‐Pyng¹²,Liu Jin‐Hwang²⁵⁶^ORCID

Affiliation:

1. Division of Hematology and Oncology Taipei Veterans General Hospital Taipei Taiwan

2. School of Medicine National Yang‐Ming University Taipei Taiwan

3. Division of Gastroenterology and Hepatology Taipei Veterans General Hospital Taipei Taiwan

4. Department of Radiology Taipei Veterans General Hospital Taipei Taiwan

5. Division of Hematology and Oncology Cheng Hsin General Hospital Taipei Taiwan

6. Chong Hin Loon Cancer and Biotherapy Research Center and Institute of Biopharmaceutical Sciences National Yang‐Ming University Taipei Taiwan

Publisher

Wiley

Subject

Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13443

Reference29 articles.

1. Hepatocellular carcinoma

2. Sorafenib in Advanced Hepatocellular Carcinoma

3. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

4. Nivolumab in sorafenib‐naive and ‐experienced patients with advanced hepatocellular carcinoma (HCC): Survival, hepatic safety, and biomarker assessments in CheckMate 040;Sangro B;Hepatology,2017

5. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of a novel 10-hydroxyevodiamine prodrug as a potent topoisomerase inhibitor with improved aqueous solubility for treatment of hepatocellular carcinoma;European Journal of Medicinal Chemistry;2024-12

2. Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line;PLOS ONE;2023-09-28

3. Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension;Biochemical Pharmacology;2022-08

4. Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities;Journal of Personalized Medicine;2021-03-22